Show simple item record

HOVON110/ReBeL Study: results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma

dc.contributor.authorStevens, WBC
dc.contributor.authorBakunina, K
dc.contributor.authorCuijpers, M
dc.contributor.authorChamuleau, M
dc.contributor.authorBeeker, A
dc.contributor.authorFijnheer, R
dc.contributor.authorHebart, H
dc.contributor.authorVisser, HPJ
dc.contributor.authorDoorduijn, JK
dc.contributor.authorLinton, Kim M
dc.contributor.authorDreyling, M
dc.contributor.authorde Jong, D
dc.contributor.authorKersten, MJ
dc.date.accessioned2020-03-27T09:28:03Z
dc.date.available2020-03-27T09:28:03Z
dc.date.issued2020en
dc.identifier.citationStevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, et al. HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. Hemasphere. 2020;4:e325.en
dc.identifier.pmid32072141en
dc.identifier.doi10.1097/HS9.0000000000000325en
dc.identifier.urihttp://hdl.handle.net/10541/622841
dc.description.abstractSupplemental Digital Content is available in the text.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/HS9.0000000000000325en
dc.titleHOVON110/ReBeL Study: results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphomaen
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlandsen
dc.identifier.journalHemasphereen
dc.description.noteen]
refterms.dateFOA2020-03-30T14:14:03Z


Files in this item

Thumbnail
Name:
32072141.pdf
Size:
982.1Kb
Format:
PDF
Description:
From UNPAYWALL
Download

This item appears in the following Collection(s)

Show simple item record